2791-57-3

Basic information

• Product Name: Hexadecane, 1-bromo-3,7,11,15-tetramethyl-
• CAS NO: 2791-57-3
• Molecular Formula: C20H41Br
• Molecular Weight: 361.45
• Mol File: 2791-57-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Hexadecane, 1-bromo-3,7,11,15-tetramethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Hexadecane, 1-bromo-3,7,11,15-tetramethyl-(2791-57-3)
• EPA Substance Registry System: Hexadecane, 1-bromo-3,7,11,15-tetramethyl-(2791-57-3)

Safety Data

• Hazardous Substances Data: 2791-57-3(Hazardous Substances Data)

Upstream product

• 150-86-7 phytol 
• 67374-00-9 phytanyl mesylate 
• 253686-88-3 (E)-3,7,11,15-tetramethylhexadec-2-en-1-ol 
• 645-72-7 3,7,11,15-tetramethyl-hexadecanol 
• 7541-49-3 3,7,11,15-tetramethyl-2-hexadecen-1-ol 

Downstream Products

• 1443677-76-6 C₈₈H₁₄₉NO₇ 

Relevant articles and documents

Discovery of Lipophilic Bisphosphonates That Target Bacterial Cell Wall and Quinone Biosynthesis

We report that alkyl-substituted bisphosphonates have activity against Bacillus anthracis Sterne (0.40 μg/mL), Mycobacterium smegmatis (1.4 μg/mL), Bacillus subtilis (1.0 μg/mL), and Staphylococcus aureus (13 μg/mL). In many cases, there is no effect of serum binding, as well as low activity against a human embryonic kidney cell line. Targeting of isoprenoid biosynthesis is involved with 74 having IC50 values of ～100 nM against heptaprenyl diphosphate synthase and 200 nM against farnesyl diphosphate synthase. B. subtilis growth inhibition was rescued by addition of farnesyl diphosphate, menaquinone-4 (MK-4), or undecaprenyl phosphate (UP), and the combination of MK-4 and UP resulted in a 25× increase in ED50, indicating targeting of both quinone and cell wall biosynthesis. Clostridioides difficile was inhibited by 74, and since this organism does not synthesize quinones, cell wall biosynthesis is the likely target. We also solved three X-ray structures of inhibitors bound to octaprenyl diphosphate and/or undecaprenyl diphosphate synthases.

Two-photon absorbing arylamine-endcapped and dialkylfluorene-bridged benzobisthiazole compounds with high oleophilicity

Two-photon absorbing arylamine-endcapped and dialkylfluorene-bridged benzobisthiazole-based compounds are provided. These two-photon absorbing benzobisthiazole-based compounds show high solubility in nonpolar hydrocarbon solvents (oleophilicity) and high two-photon properties, especially in the nanosecond domain of pulse-laser excitation.

COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B

The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.